KAM
ACOR

Kazazian Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Kazazian Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-120
Closed -$284K – 94
2018
Q3 		$284K Hold
120
– – 0.27% 69
2018
Q2 		$415K Buy
+120
New +$367K 0.38% 54

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kazazian Asset Management's ACOR Position: Q4 2018 in Review

Kazazian Asset Management sold out of Acorda Therapeutics (ACOR) in Q4 2018, closing a stake of 120 shares — an estimated $284K sold.

Kazazian Asset Management first reported a position in ACOR in Q2 2018 and held it in 2 quarters. The position peaked at $415K in Q2 2018. 179 funds tracked by Wall St. Rank hold ACOR as of Q4 2018.

  • Kazazian Asset Management reported no remaining Acorda Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Kazazian Asset Management sold 120 Acorda Therapeutics shares in Q4 2018, an estimated $284K.
  • Kazazian Asset Management first reported a position in Acorda Therapeutics in Q2 2018 and held it in 2 quarters.
  • Kazazian Asset Management's Acorda Therapeutics position peaked at $415K in Q2 2018.
  • 179 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2018.

Based on Kazazian Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.